Clinical trials: Antiviral Agents
Chronic Hepatitis C
A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects
The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of daclatasvir in subjects with chronic hepatitis C infection
- Trial name
- NCT00546715
- Testing
- Daclatasvir
- Where
- 7 sites in United States
- Volunteers
- 95 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine
To evaluate the efficacy, safety, and pharmacokinetics of lamivudine (3TC) combined with zidovudine (AZT), stavudine (d4T), or didanosine (ddI) in comparison with d4T or ddI monotherapy in HIV-infected patients with no prior…
- Trial name
- NCT00000838
- Testing
- Lamivudine, Stavudine, Zidovudine
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 256 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B Virus Infection, Pregnancy
The Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus-drug Test
Since the implementation of universal vaccination in 1984, the chronic HBV carier rate in our general population reduced from 15-20%, down to < 1% in the post-vaccination population.
- Trial name
- NCT01312012
- Testing
- antiviral therapy
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
HIV Infections
2NN & CHARM Long-Term Follow-up Study
It is desirable to obtain extended follow up data on subjects who participated in the 2NN study and the CHARM study in order to see if the beneficial effect of using nevirapine continues up to 144 weeks of treatment.
- Trial name
- NCT00127972
- Testing
- stavudine, lamivudine, nevirapine
- Where
- Australia
- Volunteers
- 763 people
- Sponsor
- International Antiviral Therapy Evaluation Center
HIV Infections
Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age
Development of tolerable and effective antiretroviral (ARV) drugs for use in children and adolescents remains a high priority. First-line therapy with non-nucleoside reverse transcriptase inhibitors (NNRTIs) has proven to be…
- Trial name
- NCT01975012
- Testing
- Rilpivirine
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
CMV Retinitis
Evaluation of Safety and Efficacy of Autologous LB-DTK-CMV in Patients With Antiviral-Resistant and Refractory Cytomegalovirus Retinitis.
The goal of this exploratory clinical study is to evaluate the safety and efficacy of Cytomegalovirus-Specific T cells (LB-DTK-CMV) to treat patients diagnosed with antiviral-resistant and refractory cytomegalovirus retinitis.
- Trial name
- NCT07679412
- Testing
- LB-DTK-CMV
- Where
- South Korea
- Volunteers
- 5 people
- Sponsor
- LucasBio
Human Immunodeficiency Virus Type 1
A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients
The purpose of this study is to evaluate the antiviral activity as measured by the change in viral load from baseline in the 14 days following initiation of treatment with 4 different dose regimens of TMC310911 co-administered…
- Trial name
- NCT00838162
- Testing
- TMC310911 75 mg twice daily, TMC310911 150 mg twice daily, TMC310911 300 mg twice daily
- Where
- 3 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Drug-Induced Liver Injury
Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs
Case control Study to assess the difference of immune cell responses between patients with chronic HCV- related liver cirrhosis who develop HCC after treatment with DAAs and those who do not develop HCC
- Trial name
- NCT03602703
- Testing
- Flow cytometry and Western Blot analysis
- Where
- Egypt
- Volunteers
- 42 people
- Sponsor
- Assiut University
HIV Infections
Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care
Many HIV infected patients admitted to the intensive care area (ICA) have never taken anti-HIV drugs. The purpose of this study is to learn whether starting anti-HIV drugs while patients are in an ICA will help them to survive…
- Trial name
- NCT00028327
- Testing
- Lamivudine/Zidovudine, Nelfinavir mesylate, Efavirenz
- Where
- 9 sites in United States
- Volunteers
- 250 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection, Neutralizing Antibody
VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...
This is the first clinical trial of the VRC-HIVMAB060-00-AB (VRC01) monoclonal antibody. VRC01 is a broadly neutralizing antibody directed against HIV.
- Conditions
- HIV-1 Infection, Neutralizing Antibody, Monoclonal Antibody, Viral Load
- Trial name
- NCT01950325
- Testing
- VRC-HIVMAB060-00-AB
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Hepatitis C
A Trial to Evaluate Safety, Tolerability, PK and Antiviral Activity of MB-110 in Hepatitis C Virus Infected Patients
A Phase 1, First-in-Human, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Ascending and Multiple Oral Doses of MB-110 in Healthy Volunteers and to…
- Trial name
- NCT02617615
- Testing
- MB-110
- Where
- Taiwan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Microbio Co Ltd
Cervical Cancer, Precancerous Condition
Cidofovir in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Receiving Chemotherapy and Radiation Therapy
RATIONALE: Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00811408
- Testing
- carboplatin, cidofovir, protein expression analysis
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Influenza
Chart Review of Antivirals for Influenza in Infants
This retrospective study conducted in Canada and the US involves a chart review to assess the safety of oseltamivir (Tamiflu®) compared to alternate antiviral therapy, amantidine or rimantidine, administered to children less than…
- Trial name
- NCT00311701
- Where
- 16 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatocellular Carcinoma, Hepatitis C
Direct-acting Antivirals and Hepatocellular Carcinoma Recurrence
Background and Aims: Arrival of direct-acting antiviral (DAA) agents against hepatitis C virus (HCV) with high-sustained virological response (SVR) rates and very few side effects has drastically changed the management of HCV…
- Conditions
- Hepatocellular Carcinoma, Hepatitis C, Direct Acting Antivirals
- Trial name
- RECAR (NCT03197155)
- Testing
- Direct Acting Antivirals against hepatitis C virus infection
- Volunteers
- 68 people
- Sponsor
- Hospices Civils de Lyon
Gastric Cancer
Pilot Study of Antiviral Treatment in Combination With Low-dose Gemcitabine in EBV-associated Gastric Cancer (EBVaGC)
Epstein-Barr virus (EBV) is a double-stranded DNA human gamma herpes virus that establishes a persistent infection in over 90% of individuals.
- Trial name
- NCT05431244
- Testing
- Antiviral treatment in combination with low-dose gemcitabine
- Where
- South Korea
- Sponsor
- Samsung Medical Center
Chronic Hepatitis B
Maintaining Antiviral Efficacy After Switching to Generic Entecavir 1 mg for Chronic Hepatitis B
Entecavir 1 mg is commonly used in patients with chronic hepatitis B (CHB) patients with previous antiviral resistance. This study evaluates the efficacy and safety of switching to generic entecavir 1 mg (Baracle®, Dong-A Science…
- Trial name
- NCT04069858
- Testing
- Switching to Generic Entecavir (Baracle®)
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Korea University
Hepatitis C
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
To demonstrate the effectiveness of DCV 3DAA fixed dose combination with or without Ribavirin in treatment naive cirrhotic subjects.
- Trial name
- NCT01973049
- Testing
- Daclatasvir, Asunaprevir, BMS-791325
- Where
- 49 sites in United States, Australia and 2 more
- Volunteers
- 202 people
- Sponsor
- Bristol-Myers Squibb
COVID-19
Antiviral Effects of TXA as a Preventative Treatment Following COVID-19 Exposure
A recent report in Physiolological Reviews proposed that the endogenous protease plasmin acts on SARS-CoV-2 by cleaving a newly inserted furin site in the S protein portion of the virus resulting in increased infectivity and…
- Trial name
- TXACOVIDPREV (NCT04550338)
- Testing
- Tranexamic acid
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Chronic Hepatitis C, Hepatitis C Virus
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy
The purpose of this study is to assess the efficacy and safety of ABT-493 and ABT-530 with or without ribavirin (RBV) in participants with chronic hepatitis C virus, (HCV)-infection who previously failed treatment with a direct…
- Conditions
- Chronic Hepatitis C, Hepatitis C Virus, HCV, Direct-Acting Antiviral Agent (DAA)-Experienced
- Trial name
- NCT02446717
- Testing
- ABT-493, ABT-530, ribavirin (RBV), ABT-493/ABT-530
- Volunteers
- 141 people
- Sponsor
- AbbVie
HIV Infections
A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC
To determine the safety of intravenous infusion of ampligen in symptomatic HIV-infected patients at several dose levels, to determine the maximum dose that can be tolerated, and to measure the effects of ampligen on the HIV virus…
- Trial name
- NCT00000735
- Testing
- Ampligen
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.